Physical activity is an important aspect of cancer therapy but correct measurement of physical activity is difficult. In this study, the physical activity of patients undergoing cancer therapy is assessed by questionnaire and by motion tracker. The results are then compared to answer whether there are differences between the two measurements. Findings of this study will help to improve the assessment of physical activity in cancer patients.
Although physical activity has been identified as a relevant determinant of cancer therapy outcome, its valid assessment remains challenging. In principle, direct and indirect assessment instruments can be employed for assessment of physical activity. While direct instruments, e.g. accelerometers, are considered to provide a more objective measurement, indirect tools such as questionnaires are less expensive and more applicable for use in larger study populations. The validity of both forms of measurements in cancer patients is however not well studied. Therefore, this study aims to elucidate the relative validity of an accelerometer in comparison to a standardized physical questionnaire at different time points of cancer therapy. Findings of this study will allow conclusions regarding the ideal modalities for assessment of physical activity in cancer patients.
Study Type
OBSERVATIONAL
Enrollment
60
No intervention - observational study only
University Medicine Greifswald
Greifswald, Germany
RECRUITINGComparison of physical activity assessments within 1 week after initiation of cancer therapy
Difference in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy
Comparison of physical activity assessments 12 weeks after initiation of cancer therapy
Difference in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 12 weeks after initiation of cancer therapy
Comparison of changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy
Difference in changes of physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 12 weeks after initiation of cancer therapy
Physical activity assessed by accelerometer
Physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Physical activity assessed by questionnaire
Physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by accelerometer
Association between ECOG Performance Status and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by questionnaire
Association between ECOG Performance Status and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Karnofsky Performance Status (KPS) to physical activity assessed by accelerometer
Association between KPS and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Karnofsky Performance Status (KPS) to physical activity assessed by questionnaire
Association between KPS and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of age to physical activity assessed by accelerometer
Association between age and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy
Relation of age to physical activity assessed by questionnaire
Association between age and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy
Relation of sex to physical activity assessed by accelerometer
Association between sex and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy
Relation of sex to physical activity assessed by questionnaire
Association between sex and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy
Relation of quality of life to physical activity assessed by accelerometer
Association between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of quality of life to physical activity assessed by questionnaire
Association between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related quality of life
Association between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and cancer therapy modality
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of fatigue to physical activity assessed by accelerometer
Association between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of fatigue to physical activity assessed by questionnaire
Association between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related fatigue
Association between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and cancer therapy modality
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep duration to physical activity assessed by accelerometer
Association between sleep duration measured by the GeneActiv accelerometer in hours and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep duration to physical activity assessed by questionnaire
Association between sleep duration measured by the GeneActiv accelerometer in hours and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep efficiency to physical activity assessed by accelerometer
Association between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep efficiency to physical activity assessed by questionnaire
Association between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related sleep duration
Association between sleep duration measured by the GeneActiv accelerometer in hours and cancer therapy modality
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related sleep efficiency
Association between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and cancer therapy modality
Time frame: 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Changes in fatigue between assessements before and 12 weeks after initiation of cancer therapy
Differences in fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12)
Time frame: 12 weeks after initiation of cancer therapy
Changes in quality of life between assessements before and 12 weeks after initiation of cancer therapy
Differences in quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30)
Time frame: 12 weeks after initiation of cancer therapy
Relation of tumor entity to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy
Association between tumor entity and changes in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 12 weeks after initiation of cancer therapy
Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy
Association between cancer therapy modality and changes in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)
Time frame: 12 weeks after initiation of cancer therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.